Literature DB >> 27277440

The ratio of the atrial areas reflects the clinical status of patients with pulmonary arterial hypertension.

Takashi Morishita1, Katsumasa Miyaji2, Izumi Akao1, Keiji Fujita1, Hiromi Nakayama1, Kenichi Hisamatsu3, Mitsuru Munemasa3, Yoshihisa Fujimoto3, Hiromi Matsubara3.   

Abstract

PURPOSE: Echocardiography is useful not only for detecting pulmonary hypertension (PH) but also for estimating the severity of PH by evaluating various morphological changes of the heart caused by pressure and volume overload and by ventricular interaction. We investigated whether a novel echocardiographic index, i.e., the ratio of the atrial areas (RA/LA), would be useful for evaluating the clinical status of patients with pulmonary arterial hypertension (PAH) treated with intravenous epoprostenol.
METHODS: We introduced epoprostenol therapy for seven PAH patients without severe tricuspid regurgitation. We evaluated clinical criteria indicative of prognosis, for example World Health Organization functional class (WHO-FC), brain natriuretic peptide (BNP) level, echocardiographic indices such as indexed RA area and RA/LA, and hemodynamics before and one year after intravenous epoprostenol therapy.
RESULTS: There were significant improvements in both RA/LA (2.5 ± 1.0, 1.3 ± 0.4, P < 0.001) and indexed RA area (22.5 ± 8.9, 14.5 ± 5.8, P < 0.001). The improvement in RA/LA was more sensitive than that in indexed RA area (P < 0.01). Moreover, RA/LA was significantly correlated with WHO-FC (r = 0.50, P < 0.01) and BNP level (r = 0.82, P < 0.01).
CONCLUSIONS: RA/LA is useful for evaluating the clinical status of patients with PAH treated with intravenous epoprostenol.

Entities:  

Keywords:  Echocardiography; Pulmonary arterial hypertension; Ratio of the atrial areas

Year:  2009        PMID: 27277440     DOI: 10.1007/s10396-009-0228-0

Source DB:  PubMed          Journal:  J Med Ultrason (2001)        ISSN: 1346-4523            Impact factor:   1.314


  15 in total

1.  Prevention of catheter-related infections using a closed hub system in patients with pulmonary arterial hypertension.

Authors:  Satoshi Akagi; Hiromi Matsubara; Aiko Ogawa; Yusuke Kawai; Kenichi Hisamatsu; Katsumasa Miyaji; Mitsuru Munemasa; Yoshihisa Fujimoto; Kengo Fukushima Kusano; Tohru Ohe
Journal:  Circ J       Date:  2007-04       Impact factor: 2.993

2.  Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension.

Authors:  S B Eysmann; H I Palevsky; N Reichek; K Hackney; P S Douglas
Journal:  Circulation       Date:  1989-08       Impact factor: 29.690

3.  An echocardiographic index for separation of right ventricular volume and pressure overload.

Authors:  T Ryan; O Petrovic; J C Dillon; H Feigenbaum; M J Conley; W F Armstrong
Journal:  J Am Coll Cardiol       Date:  1985-04       Impact factor: 24.094

4.  Echocardiographic features of primary pulmonary hypertension.

Authors:  E Bossone; T H Duong-Wagner; G Paciocco; H Oral; M Ricciardi; D S Bach; M Rubenfire; W F Armstrong
Journal:  J Am Soc Echocardiogr       Date:  1999-08       Impact factor: 5.251

5.  Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension.

Authors:  N Nagaya; T Nishikimi; M Uematsu; T Satoh; S Kyotani; F Sakamaki; M Kakishita; K Fukushima; Y Okano; N Nakanishi; K Miyatake; K Kangawa
Journal:  Circulation       Date:  2000-08-22       Impact factor: 29.690

6.  Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension.

Authors:  Ronald J Raymond; Alan L Hinderliter; Park W Willis; David Ralph; Edgar J Caldwell; William Williams; Neil A Ettinger; Nicholas S Hill; Warren R Summer; Bennett de Boisblanc; Todd Schwartz; Gary Koch; Linda M Clayton; Maria M Jöbsis; James W Crow; Walker Long
Journal:  J Am Coll Cardiol       Date:  2002-04-03       Impact factor: 24.094

7.  Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. PPH Study Group. Primary pulmonary hypertension.

Authors:  A L Hinderliter; P W Willis; W Long; W R Clarke; D Ralph; E J Caldwell; W Williams; N A Ettinger; N S Hill; W R Summer; B de Biosblanc; G Koch; S Li; L M Clayton; M M Jöbsis; J W Crow
Journal:  Am J Cardiol       Date:  1999-08-15       Impact factor: 2.778

8.  Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group.

Authors:  A L Hinderliter; P W Willis; R J Barst; S Rich; L J Rubin; D B Badesch; B M Groves; M D McGoon; V F Tapson; R C Bourge; B H Brundage; S K Koerner; D Langleben; C A Keller; S Murali; B F Uretsky; G Koch; S Li; L M Clayton; M M Jöbsis; S D Blackburn; J W Crow; W A Long
Journal:  Circulation       Date:  1997-03-18       Impact factor: 29.690

Review 9.  Diagnosis and differential assessment of pulmonary arterial hypertension.

Authors:  Robyn J Barst; Michael McGoon; Adam Torbicki; Olivier Sitbon; Michael J Krowka; Horst Olschewski; Sean Gaine
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

10.  Clinical significance of brain natriuretic peptide in primary pulmonary hypertension.

Authors:  Hanno H Leuchte; Michael Holzapfel; Rainer A Baumgartner; Isabelle Ding; Claus Neurohr; Michael Vogeser; Tilman Kolbe; Martin Schwaiblmair; Jürgen Behr
Journal:  J Am Coll Cardiol       Date:  2004-03-03       Impact factor: 24.094

View more
  1 in total

1.  Monocrotaline-induced pulmonary hypertension with sufficient tricuspid regurgitation in a rat model.

Authors:  Fuminobu Ishikura; Ryoko Azakami; Toshihiko Asanuma; Shintaro Beppu
Journal:  J Med Ultrason (2001)       Date:  2012-05-24       Impact factor: 1.314

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.